<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02970851</url>
  </required_header>
  <id_info>
    <org_study_id>08/12</org_study_id>
    <nct_id>NCT02970851</nct_id>
  </id_info>
  <brief_title>Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-FDG and 82Rb PET/CT on PAH and CTEPH</brief_title>
  <official_title>Effect of Endothelin Receptor Antagonist Bosentan in Glucose Metabolism of the Myocardium and Coronary Dependant Endothelial Vasoreactivity Measured by 18F-FDG PET / CT and 82Rb PET / CT in Patients With PAH or CTEPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of bosentan on the myocardial metabolism&#xD;
      and the dependent endothelial coronary vasomotoricity in patients presenting a PAH.&#xD;
&#xD;
      Hypothesis : Bosentan may improve right ventricular function by decreasing myocardial stress&#xD;
      and glucose metabolism. Patients may benefit from images with 18F-FDG PET / CT and 82Rb PET /&#xD;
      CT for an earlier assessment and optimal management of PAH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients refered to the hospital for a right heart catheterization for a PAH suspected at the&#xD;
      echocardiography will be presented with the protocol.If inclusion/exclusion criteria are&#xD;
      fulfilled all the procedures will be planned. At the screening visit the patient will have a&#xD;
      right heart catheterization and an echocardiography. After a maximum of 4 weeks each patient&#xD;
      will have 18F-FDG and 82Rb PET/CTs before start of treatment with Bosentan. These PET/CTs&#xD;
      together with an echocardiography will be repeated at 6 and 12 weeks after start of treatment&#xD;
      with bosentan.&#xD;
&#xD;
      Finally a right heart catheterization will be planned at 12 weeks after start of treatment&#xD;
      with bosentan as a routine procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow patient recruitment after arrival of macitentan on the market&#xD;
  </why_stopped>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism</measure>
    <time_frame>Baseline</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>myocardial ventricular right maximum standardized uptake value (SUVmax) on the images of au 18F-FDG PET/CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT rest MBF</measure>
    <time_frame>Baseline</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT rest MBF</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT rest MBF</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT rest MBF</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT stress MBF</measure>
    <time_frame>Baseline</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at pharmacological stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT stress MBF</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at pharmacological stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT stress MBF</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at pharmacological stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT stress MBF</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at pharmacological stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF</measure>
    <time_frame>Baseline</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at cold test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at cold test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at cold test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at cold test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction</measure>
    <time_frame>Baseline</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters PAP</measure>
    <time_frame>at screening</time_frame>
    <description>pulmonary arterial pressure (PAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters PAP</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>PAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters RAP</measure>
    <time_frame>at screening</time_frame>
    <description>right atrial pressure (RAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters RAP</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>RAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters PWP</measure>
    <time_frame>at screening</time_frame>
    <description>pulmonary wedge pressure (PWP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters PWP</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>PWP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters NYHA</measure>
    <time_frame>at screening</time_frame>
    <description>NYHA classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters NYHA</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>New York Heart Association (NYHA) classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters 6-min walk test</measure>
    <time_frame>at screening</time_frame>
    <description>6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters 6-min walk test</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters LFT</measure>
    <time_frame>at screening</time_frame>
    <description>Results of lung function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters LFT</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>Results of lung function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters NT-pro-BNP</measure>
    <time_frame>at screening</time_frame>
    <description>plasmatic N terminal - pro - Brain Natriuretic Peptide (NT-pro-BNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters NT-pro-BNP</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>plasmatic NT-pro-BNP</description>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Myocardial Dysfunction</condition>
  <condition>Endothelial Dysfunction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for Bosentan therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic PAH (PH group 1 Dana Point / stages 2 à 4 according to NYHA&#xD;
             classification, defined by a mean arterial pulmonary pressure &gt;25 millimeter of&#xD;
             mercury (mmHg) at rest, an occlusion arterial pulmonary pressure &lt;15 millimeter of&#xD;
             mercury (mmHg) and vascular pulmonary resistance &gt;240 dyn.s.cm-5 for which a treatment&#xD;
             with bosentan is indicated Or Patients with CTEPH not candidate for a pulmonary&#xD;
             endarterectomy or patient with residual CTEPH after pulmonary endarterectomy (PH group&#xD;
             4 Dana Point / stages 2 to 4 according to NYHA classification) and for which a&#xD;
             treatment with bosentan is indicated&#xD;
&#xD;
          -  Indication to perform a right heart catheterization in the context of PAH suspected&#xD;
             during cardiac ultrasound&#xD;
&#xD;
          -  Age from 18 to 80 years old, male and female&#xD;
&#xD;
          -  Karnofsky index ≥80%&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with PAH stages 2,3 or 5 of Dana Point&#xD;
&#xD;
          -  Patients with a contra-indication to adenosine including severe uncontrolled asthma,&#xD;
             severe uncontrolled chronic obstructive pulmonary disease, 2nd or 3rd degree&#xD;
             atrioventricular block without pacemaker,&#xD;
&#xD;
          -  Patients with a contraindication to Bosentan, i.e :hypersensibility to the product,&#xD;
             hepatic failure Child Pugh B or C, aminotransferases &gt;3 times normal value&#xD;
             (N),association with cyclosporine A or glibenclamide&#xD;
&#xD;
          -  Pregnancy, female of child-bearing potential not using any acceptable contraceptive&#xD;
             method, breastfeeding&#xD;
&#xD;
          -  Atrial fibrillation (Ventricular Ejection Fraction (VEF) not evaluable at echography)&#xD;
&#xD;
          -  Karnofsky index &lt;80%&#xD;
&#xD;
          -  Impossibility to obtain informed consent signed&#xD;
&#xD;
          -  Left cardiopathies that can be responsible of post-capillar hypertension&#xD;
&#xD;
          -  Involvement in another clinical study with an unregistered drug within 30 days prior&#xD;
             to this specific study and during the entire course of the study&#xD;
&#xD;
          -  Inability to comply with study procedures (linguistic problem, psychiatric problems,&#xD;
             dementia, confusional state)&#xD;
&#xD;
          -  Known or suspected non compliance drug or alcohol abuse&#xD;
&#xD;
          -  Left heart assessment : diastolic and systolic function and valvular structures to&#xD;
             exclude a cardiac pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John O Prior, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lausanne University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://erj.ersjournals.com/content/50/suppl_61/PA2414</url>
    <description>abstract poster presentation about present study</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>John O. Prior</investigator_full_name>
    <investigator_title>Chief of the Department of Nuclear medicine</investigator_title>
  </responsible_party>
  <keyword>Endothelin receptor antagonist (ERA)</keyword>
  <keyword>pulmonary artery hypertension (PAH),</keyword>
  <keyword>18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT</keyword>
  <keyword>Rubidium-82 (82Rb) PET/CT</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02970851
org study id: 08/12
nct id: NCT02970851
lead sponsor: 
has dmc: No
The purpose of this study is to assess the effect of bosentan on the myocardial metabolism
      and the dependent endothelial coronary vasomotoricity in patients presenting a PAH.

      Hypothesis : Bosentan may improve right ventricular function by decreasing myocardial stress
      and glucose metabolism. Patients may benefit from images with 18F-FDG PET / CT and 82Rb PET /
      CT for an earlier assessment and optimal management of PAH.
Patients refered to the hospital for a right heart catheterization for a PAH suspected at the
      echocardiography will be presented with the protocol.If inclusion/exclusion criteria are
      fulfilled all the procedures will be planned. At the screening visit the patient will have a
      right heart catheterization and an echocardiography. After a maximum of 4 weeks each patient
      will have 18F-FDG and 82Rb PET/CTs before start of treatment with Bosentan. These PET/CTs
      together with an echocardiography will be repeated at 6 and 12 weeks after start of treatment
      with bosentan.

      Finally a right heart catheterization will be planned at 12 weeks after start of treatment
      with bosentan as a routine procedure.
observational model: Cohort
time perspective: Prospective
measure: Analysis of each method of imaging for assessment of myocardial metabolism
time frame: Baseline
description: On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)
measure: Analysis of each method of imaging for assessment of myocardial metabolism
time frame: at 4 weeks after start of treatment
description: myocardial ventricular right maximum standardized uptake value (SUVmax) on the images of au 18F-FDG PET/CT
measure: Analysis of each method of imaging for assessment of myocardial metabolism
time frame: at 6 weeks after start of treatment
description: On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)
measure: Analysis of each method of imaging for assessment of myocardial metabolism
time frame: at 12 weeks after start of treatment
description: On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)
measure: On the images 82Rb PET/CT rest MBF
time frame: Baseline
description: myocardial blood flow (MBF in mL/min/g) at rest
measure: On the images 82Rb PET/CT rest MBF
time frame: at 4 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at rest
measure: On the images 82Rb PET/CT rest MBF
time frame: at 6 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at rest
measure: On the images 82Rb PET/CT rest MBF
time frame: at 12 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at rest
measure: On the images 82Rb PET/CT stress MBF
time frame: Baseline
description: myocardial blood flow (MBF in mL/min/g) at pharmacological stress
measure: On the images 82Rb PET/CT stress MBF
time frame: at 4 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at pharmacological stress
measure: On the images 82Rb PET/CT stress MBF
time frame: at 6 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at pharmacological stress
measure: On the images 82Rb PET/CT stress MBF
time frame: at 12 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at pharmacological stress
measure: On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF
time frame: Baseline
description: myocardial blood flow (MBF in mL/min/g) at cold test
measure: On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF
time frame: at 4 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at cold test
measure: On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF
time frame: at 6 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at cold test
measure: On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF
time frame: at 12 weeks after start of treatment
description: myocardial blood flow (MBF in mL/min/g) at cold test
measure: Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction
time frame: Baseline
description: On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)
measure: Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction
time frame: at 4 weeks after start of treatment
description: On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)
measure: Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction
time frame: at 6 weeks after start of treatment
description: On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)
measure: Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction
time frame: at 12 weeks after start of treatment
description: On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)
measure: Analysis of right heart catheterization parameters PAP
time frame: at screening
description: pulmonary arterial pressure (PAP)
measure: Analysis of right heart catheterization parameters PAP
time frame: at 12 weeks after start of treatment
description: PAP
measure: Analysis of right heart catheterization parameters RAP
time frame: at screening
description: right atrial pressure (RAP)
measure: Analysis of right heart catheterization parameters RAP
time frame: at 12 weeks after start of treatment
description: RAP
measure: Analysis of right heart catheterization parameters PWP
time frame: at screening
description: pulmonary wedge pressure (PWP)
measure: Analysis of right heart catheterization parameters PWP
time frame: at 12 weeks after start of treatment
description: PWP
measure: Analysis of clinical parameters NYHA
time frame: at screening
description: NYHA classification
measure: Analysis of clinical parameters NYHA
time frame: at 12 weeks after start of treatment
description: New York Heart Association (NYHA) classification
measure: Analysis of clinical parameters 6-min walk test
time frame: at screening
description: 6-minute walk test
measure: Analysis of clinical parameters 6-min walk test
time frame: at 12 weeks after start of treatment
description: 6-minute walk test
measure: Analysis of clinical parameters LFT
time frame: at screening
description: Results of lung function tests
measure: Analysis of clinical parameters LFT
time frame: at 12 weeks after start of treatment
description: Results of lung function tests
measure: Analysis of clinical parameters NT-pro-BNP
time frame: at screening
description: plasmatic N terminal - pro - Brain Natriuretic Peptide (NT-pro-BNP)
measure: Analysis of clinical parameters NT-pro-BNP
time frame: at 12 weeks after start of treatment
description: plasmatic NT-pro-BNP
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: John O Prior, MD PhD
role: Principal Investigator
affiliation: Lausanne University Hospitals
facility: 
country: Switzerland
url: https://erj.ersjournals.com/content/50/suppl_61/PA2414
description: abstract poster presentation about present study
responsible party type: Principal Investigator
investigator affiliation: University of Lausanne Hospitals
investigator full name: John O. Prior
investigator title: Chief of the Department of Nuclear medicine
sharing ipd: No